Journal Article

Treatment Patterns and Clinical Outcomes in Patients with Hodgkin Lymphoma from Saudi Arabia, Türkiye, and South Africa: Subgroup Analysis from the International Multicenter Retrospective B-HOLISTIC Study

Ferhanoğlu, Burhan, Brittain, David, Rauf, M Shahzad, Al-Mansour, Mubarak, Boğa, Can, Akhtar, Saad, Maghfoor, Irfan, Moodley, Dhaya, Singh, Jaimendra Prithipal, Patel, Moosa, Mohamed, Zainab, Saydam, Güray, Rodrigues, Sylvia, Dreosti, Lydia M, Alzahrani, Mohsen, Kalayoğlu Beşışık, Sevgi, Pinchevsky, Yacob, Huang, Zhongwen

2024

Overview

B-HOLISTIC was a real-world retrospective study of treatment patterns and clinical outcomes in Hodgkin lymphoma (HL) in regions outside Europe and North America. This subgroup analysis reports findings from Saudi Arabia, Türkiye, and South Africa. Patients aged ≥18 years and diagnosed with stage IIB-IV classical HL receiving frontline chemotherapy (frontline cHL) and/or with relapsed/refractory HL (RRHL) from January 2010 to December 2013 were assessed. The primary endpoint was progression-free survival (PFS) in patients with RRHL. Overall, 694 patients (RRHL: n=178; frontline cHL: n=653) were enrolled. Among patients with RRHL, >80% received first salvage chemotherapy. The most common first salvage regimens were etoposide, methylprednisolone, cytarabine, and cisplatin in Saudi Arabia (78.3%) and dexamethasone, cytarabine, and cisplatin in Türkiye (36.1%) and South Africa (40%). Median PFS (95% confidence interval [CI]) in the RRHL group was 5.1 (3.0-15.9), 19.7 (7.5-not reached), and 5.2 (1.1-10.1) months in Saudi Arabia, Türkiye, and South Africa, respectively. The 5-year PFS and overall survival (95% CI) rates in patients with RRHL were 33.2% (21.6-45.2) and 78.2% (65.9-86.5) in Saudi Arabia, 42.5% (29.5-54.9) and 79.4% (67.2-87.5) in Türkiye, and 13.1% (4.2-27.0) and 53% (35.5-67.8) in South Africa, respectively. This study showed that the clinical outcomes in Türkiye and Saudi Arabia were generally comparable with those of Western countries during the study period, although Saudi Arabia had lower PFS rates. Conversely, the clinical outcomes in South Africa were suboptimal, emphasizing the need for novel therapies and improved progression to stem cell transplantation. These data may serve as a control group for future studies in these countries and inform clinical decision-making.

• Publisher: Galenos Publishing House,Galenos Publishing,Turkish Society of Hematology
• Subject: Adolescent / Adult / Aged / Antineoplastic Combined Chemotherapy Protocols - therapeutic use / Chemotherapy / Clinical decision making / Clinical outcomes / developing countries / Female / hematological neoplasms / hematopoietic stem cell transplantation / Hodgkin Disease - drug therapy / Hodgkin Disease - epidemiology / Hodgkin Disease - mortality / Hodgkin Disease - therapy / Humans / Lymphoma / Male / Middle Aged / Neoplasm Staging / real-world evidence / resource limitations / Retrospective Studies / Salvage Therapy / Saudi Arabia - epidemiology / South Africa - epidemiology / Stem cell transplantation / Treatment Outcome / Young Adult